A group of senior investment bankers who worked on Verizon’s $130 billion deal with Vodafone last year are back in the boardroom for another potential $100 billion deal – Pfizer's approach for AstraZeneca.
Pfizer, the US pharmaceuticals giant this morning confirmed it had contacted AstraZeneca on April 26 seeking to renew discussions about a possible merger. The Wall Street Journal reported that a deal could be worth over $100 billion.
